Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Biomedical research : HHS has not yet used new authorities to improve recruitment and retention of scientists / / Mary Denigan-Macauley
| Biomedical research : HHS has not yet used new authorities to improve recruitment and retention of scientists / / Mary Denigan-Macauley |
| Pubbl/distr/stampa | Washington, DC : , : U.S. Government Accountability Office, , 2020 |
| Descrizione fisica | 1 online resource (4 pages) |
| Soggetto topico |
Medical scientists - United States
Biology - Research - United States Medicine - Research - United States |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Biomedical Research |
| Record Nr. | UNINA-9910717462903321 |
| Washington, DC : , : U.S. Government Accountability Office, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
COVID-19 : Federal Efforts Accelerate Vaccine and Therapeutic Development, but More Transparency Needed on Emergency Use Authorizations : report to congressional addressees
| COVID-19 : Federal Efforts Accelerate Vaccine and Therapeutic Development, but More Transparency Needed on Emergency Use Authorizations : report to congressional addressees |
| Pubbl/distr/stampa | Washington, DC : , : United States Government Accountability Office, , 2020 |
| Descrizione fisica | 1 online resource (ii, 46 pages) : color illustrations |
| Soggetto topico |
COVID-19 (Disease) - Prevention - Government policy - United States
COVID-19 (Disease) - Treatment - Government policy - United States COVID-19 (Disease) - Research - Government policy - United States Emergency management - United States Transparency in government - United States COVID-19 (Disease) - Prevention - Government policy Emergency management Transparency in government |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | COVID-19 |
| Record Nr. | UNINA-9910717174403321 |
| Washington, DC : , : United States Government Accountability Office, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Drug safety: COVID-19 complicates already challenged FDA foreign inspection program : testimony before the Committee on Finance, U.S. Senate / / statement of Mary Denigan-Macauley
| Drug safety: COVID-19 complicates already challenged FDA foreign inspection program : testimony before the Committee on Finance, U.S. Senate / / statement of Mary Denigan-Macauley |
| Pubbl/distr/stampa | [Washington, D.C.] : , : United States Government Accountability Office, , 2020 |
| Descrizione fisica | 1 online resource (26 pages) : color illustrations, color maps |
| Collana | Testimony |
| Soggetto topico |
COVID-19 (Disease) - Treatment - United States
Drugs - Inspection - United States Drugs - United States - Safety measures - Evaluation Pharmaceutical industry - Quality control - Evaluation Drugs - Safety regulations - United States - Evaluation Drug reimportation - United States - Evaluation Imports - United States - Safety measures - Evaluation |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Drug safety |
| Record Nr. | UNINA-9910713508703321 |
| [Washington, D.C.] : , : United States Government Accountability Office, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Drug safety: FDA's future inspection plans need to address issues presented by COVID-19 backlog : testimony before the Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies, Committee on Appropriations, House of Representatives / / statement of Mary Denigan-Macauley
| Drug safety: FDA's future inspection plans need to address issues presented by COVID-19 backlog : testimony before the Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies, Committee on Appropriations, House of Representatives / / statement of Mary Denigan-Macauley |
| Pubbl/distr/stampa | [Washington, D.C.] : , : United States Government Accountability Office, , 2021 |
| Descrizione fisica | 1 online resource (18 pages) : color illustrations, color map |
| Collana | Testimony |
| Soggetto topico |
COVID-19 (Disease) - Treatment - United States
COVID-19 Pandemic, 2020- - United States Drugs - Inspection - United States Drugs - United States - Safety measures Drug reimportation - United States |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Drug safety |
| Record Nr. | UNINA-9910715327503321 |
| [Washington, D.C.] : , : United States Government Accountability Office, , 2021 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Prescription opioids: medicare needs better information to reduce the risk of harm to beneficiaries : testimony before the Subcommittee on Health Care, Committee on Finance, U.S. Senate / / / statement of Mary Denigan-Macauley
| Prescription opioids: medicare needs better information to reduce the risk of harm to beneficiaries : testimony before the Subcommittee on Health Care, Committee on Finance, U.S. Senate / / / statement of Mary Denigan-Macauley |
| Pubbl/distr/stampa | [Washington, D.C.] : , : United States Government Accountability Office, , 2018 |
| Descrizione fisica | 1 online resource (13 pages) : color illustrations |
| Collana | Testimony |
| Soggetto topico |
Opioid abuse - United States - Prevention
Medication abuse - United States - Prevention |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Prescription opioids |
| Record Nr. | UNINA-9910711994103321 |
| [Washington, D.C.] : , : United States Government Accountability Office, , 2018 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||